by lfow cytometry. According to CAG morphology, the plaques included 3 types as Type I, Type II and TypeⅢ. The patients also received coronary CT angiography (CTA), upon CTA value, the plaques were classiifed by soft plaque, ifbrous plaque and calciifed plaque. Expressions of platelet surface EMMPRIN and GPVI among different groups were compared.
Results:①Compared with Control group, ACS and SAP groups had increased expressions of EMMPRIN (5.82 ± 0.81 and 3.45 ± 0.48) vs (1.35 ± 0.15) and GPVI (16.22 ± 5.27 and 8.20 ± 2.87) vs (4.14 ±1.17); the expressions in ACS group were higher than those in SAP group, allP<0.05.②In ACS group, compared with Type I plaque, the patients with Type II and TypeⅢ plaques had elevated levels of EMMPRIN (6.35 ± 1.05 and 4.09 ± 0.67) vs (2.45 ± 0.27) and GPVI (19.50 ± 4.55 and 10.81 ± 2.33) vs (5.89 ± 1.28); the expressions in patients with Type II plaque was higher than those with Type III plaque, allP<0.05.③In ACS group, compared with calciifed plaque, the patients with soft and ifbrous plaques had the higher levels of EMMPRIN (6.18 ± 1.01 and 3.87 ± 0.56) vs (2.43 ± 0.25) and GPVI (19.14 ± 4.27 and 11.08 ± 1.94) vs (5.96 ± 0.99); the expressions in patients with soft plaque was higher than those with ifbrous plaque, allP<0.05.④In CAD patients, EMMPRIN expression was negatively related to plaque type (95% CI: -0.359 to -0.206, β: -0.211) and positively related to clinical type (95% CI: 0.893-1.034, β: 0.893); GPVI expression was negatively related to plaque type (95% CI: -1.222 to -0.586, β: -0.181) and positively related to clinical type (95% CI: 3.576-4.164, β: 0.960).
Conclusion: Expression levels of platelet surface EMMPRIN and GPVI were closely related to the stability of coronary plaque, both of them were the risk factors for severe coronary lesions. EMMPRIN and GPVI may have certain predictive value for early diagnosis of arteriosclerosis in ACS patients.